ASX:SNT News | QuoteStream

quartr

SNT: Lead asset amsulostat shows strong Phase 2 efficacy and safety, with multiple pipeline catalysts ahead

A diversified clinical-stage pipeline is advancing with strong institutional backing and cash runway into FY28. Lead asset amsulostat shows promising efficacy and safety in myelofibrosis, with expansion into MDS and neurodegenerative diseases, and multiple near-term clinical catalysts expected.Orig…

Quartr en_IN 27/7/2026, 07:52 am GMT+8

StocksAU

SNT

quartr

SNT: FDA supports late-stage trial; strong cash position and key clinical readouts expected in H2 2026

FDA feedback supports late-stage amsulostat trial; SNT-4728 shows significant anti-inflammatory effect in Parkinson's-related brain regions. Cash runway extended into Q3 2027 after $8.8M capital raise, with multiple clinical catalysts expected in H2 2026.Original document: Syntara Limited [SNT] Ear…

Quartr en_IN 27/7/2026, 07:51 am GMT+8

StocksAU